Liniment Veterinary Grade API, designated as model L-VET-100 for oral solid dosage forms and premix, L-VET-200 for oral solutions and topical liniments, and L-VET-300 for sterile injectables, is supplied as a rectified botanical active fraction with a controlled terpene marker profile. Unlike finished liniment dosage forms, this material is the active substance from which tablets, capsules, powders, granules, premix, solutions, and injections are manufactured. The liquid presentations are specified as clear, pale yellow to light amber liquids; the carrier-loaded oral solid grade is a white to off-white free-flowing powder produced by depositing the liquid active fraction onto microcrystalline cellulose or colloidal silicon dioxide. Assay of the principal marker compound is controlled within 98.0–102.0% for L-VET-300 and 95.0–105.0% for the carrier-loaded L-VET-100. Release limits include acid value, peroxide value, aldehydes, residue on ignition, heavy metals, residual solvents, microbial enumeration, and bacterial endotoxins as appropriate to the route of administration. The manufacturing route follows veterinary GMP under FDA 21 CFR 210–211, and the impurity profile is aligned with VICH GL18 for residual solvents and VICH GL3 for stability, with stability data generated according to the bracketing design of VICH GL3 where multi-dose containers are involved.

This monograph defines the material as a pharmaceutical intermediate, not as a compounded preparation. The rationale for dedicated veterinary grade specifications is the wide variation in manufacturing conditions across multi-species dosage forms. A single technical-grade feedstock cannot satisfy the particulate, endotoxin, impurity, and oxidative-stability demands of sterile injection and solid feed premix operations simultaneously. Because this product is a veterinary API intermediate, published data for this specific configuration is limited. The processing ranges stated in this technical note derive from current pharmacopoeial monographs, equipment manufacturer technical bulletins, and standard pharmaceutical unit operation references; each applicant must verify the selected ranges through process validation under the intended marketing authorization.

How does a veterinary liniment API differ from industrial-grade terpene feedstocks?

The principal distinction is not terpene concentration but the removal of oxidation products, resin acids, and pro-inflammatory low-molecular-weight carbonyls. Industrial-grade terpene feedstocks stored in unlined steel drums commonly exhibit peroxide values above 10 mEq/kg, whereas the veterinary API grade is controlled to ≤ 2 mEq/kg using a titrimetric method aligned with Ph. Eur. 2.5.5. The purification sequence includes wiped-film molecular distillation at 0.5–5 mbar jacket temperature 80–130 °C and nitrogen-blanketed storage to limit re-oxidation. Heavy metal residues from storage and transport are reduced by chelation and filtration; iron is specified at ≤ 2 ppm and copper at ≤ 1 ppm by microwave-assisted ICP-MS. These trace metals accelerate autoxidation in liquid and adsorbed solid formulations. Moreover, the technical grade has no microbial specification, whereas the veterinary API grade must meet USP <61> and <62> for total aerobic microbial count below 100 CFU/g and yeast and mold count below 10 CFU/g, with absence of Salmonella and Escherichia coli in 25 g. Compared with single-entity synthetic liniment actives such as methyl salicylate, this API is a complex botanical fraction requiring fingerprint analysis rather than a single HPLC peak; the difference is a defined multi-marker profile, while the limitation is the need to blend multiple distillate lots to control batch-to-batch variance. The resulting difference in tablet and capsule processing is measurable: accelerated stability at 40 °C/75% RH for 6 months maintains CIELAB ΔE below 3.0 for the veterinary grade, while technical-grade material can exceed 8.0 under the same conditions.

Release of Liniment Veterinary Grade API to the formulation department requires a compendially aligned analytical panel rather than a single assay. Because the active substance is a complex mixture, fingerprint consistency is performed by gas chromatography with flame ionization detection against a certified reference standard. Retention times and relative areas of the marker peaks must fall within acceptance windows established during process validation. The liquid grades are additionally controlled for density at 20 °C between 0.850–0.880 g/cm³ using a digital densimeter according to Ph. Eur. 2.2.5, for refractive index between 1.470–1.485 according to Ph. Eur. 2.2.6, and for water content by USP <921> Method Ia not exceeding 0.3%. The carrier-loaded L-VET-100 grade permits water content up to 2.0% because residual water is removed during granulation; higher moisture is rejected because it accelerates hydrolytic degradation of the carrier-bound active phase. Stability-limiting impurities are not limited solely by assay. The peroxide value is controlled to ≤ 2 mEq/kg at release and ≤ 5 mEq/kg at shelf life. Aldehyde content measured as anisaldehyde equivalents remains below 0.1% to reduce crosslinking in gelatin capsules and imine formation in amine-containing feed premixes. The acid value is held below 1.0 mg KOH/g because free acids cause hydrolytic degradation of ester-based carriers. Residue on ignition is limited to ≤ 0.05% to prevent visible particles in injectables and nozzle wear in fluid-bed spraying.

When the liquid active substance is converted to free-flowing adsorbed solids

L-VET-100 carrier-loaded grade is prepared by spraying the liquid active fraction onto microcrystalline cellulose or colloidal silicon dioxide in a low-shear tumbler or high-shear mixer. The liquid load is typically 30–50% w/w; above 50% w/w, the powder can become cohesive and flow index drops below 10 mm by Ph. Eur. 2.9.16. Before tableting, the carrier-loaded material is passed through a 1.0 mm oscillating screen. For direct compression, the liberated material is required to have a bulk density of 0.35–0.55 g/mL and tapped density below 0.75 g/mL. The Carr index is held between 15–25% to avoid segregation in tablet press feed frames; the Hausner ratio must not exceed 1.35. In wet granulation, the API-loaded carrier is mixed at impeller speeds of 150–400 rpm with binder solution; granulation endpoint is determined by torque rise of 20–30% on a 4.5 L high-shear mixer. Drying is performed in a fluid-bed dryer with inlet air 55–70 °C, with bed dew point monitored. Residual moisture is maintained at 2.0–3.0% for capsules and 1.5–2.5% for film-coated tablets. The primary process conflict is between tablet hardness and active fraction release. Higher compaction pressure above 150 MPa can fracture the carrier particles and release the liquid active phase, causing picking and sticking on the tablet punches. A compaction pressure of 80–130 MPa and a turret speed of 20–40 rpm are typically sufficient to produce tablets with hardness 50–80 N according to Ph. Eur. 2.9.8 while preserving the carrier structure. In capsules, the powder is filled on an intermittent-motion encapsulation machine with tamping stations; the plug density is controlled between 0.45–0.60 g/mL to maintain weight variation below 3%. For aqueous film-coated tablets, the coating pan is operated at inlet air temperature 60–70 °C and pan speed 6–12 rpm. The API is prone to oxidative discolouration during extended drying; therefore, nitrogen-blanketed tray dryers are used when scale-up exceeds 100 kg batch size.

Oral solutions and premix formulations use L-VET-200. The liquid is miscible with ethanol and propylene glycol but has limited aqueous solubility. Aqueous dispersions are prepared by pre-emulsification with polysorbate 80 at 0.5–2.0% w/w; the resulting droplet size measured by laser diffraction is maintained below 20 µm. Premix carriers use precipitated silica at 0.5–1.0% to prevent oil breakthrough during storage at 30 °C/65% RH. The premix is packaged in multi-layer paper sacks with an inner polyethylene liner; storage at 30 °C/65% RH is validated for 24 months. The product should not be stored above 40 °C because peroxides form and reduce marker content.

L-VET-300 sterile injectable grade is dissolved in a co-solvent system containing propylene glycol and water for injection at a concentration normally not exceeding 10% v/v active fraction. Higher concentrations may reduce 0.22 µm membrane filter throughput because viscosity rises above 15 mPa·s at 25 °C. Sterile filtration is performed through PVDF or PES membrane with a rated pore size of 0.22 µm; filter compatibility testing according to PDA Technical Report 26 is completed before manufacturing. The filtered solution is held in a nitrogen-purged vessel at 2–8 °C for no longer than 24 h before filling. Terminal autoclaving is avoided for non-aqueous formulations because the API undergoes isomerization and aldehyde formation above 121 °C at pH above 6.0; aseptic filtration is therefore the default for heat-sensitive formulations. Filling is conducted under Grade A laminar flow according to EU GMP Annex 1. Endotoxin control uses USP <85> with a limit of ≤ 0.25 EU/mg for the active substance. The injectable grade is also tested for particulate matter using Ph. Eur. 2.9.19 and for visible particles by light obscuration; no more than 10 particles per container ≥ 10 µm and 2 particles per container ≥ 25 µm are permitted in the final filled solution. Compatibility with glass vials and rubber stoppers is verified by extractables and leachables studies under USP <1664> and Ph. Eur. 3.2.9. The API should not be combined with amine-based buffers because imine formation can reduce assay within 48 h. Exposure to strong oxidizing agents or unlined carbon steel should be avoided, because both increase peroxide value and deepen the material colour beyond the L-VET-300 release specification.